Short Interest in Outset Medical, Inc. (NASDAQ:OM) Drops By 13.6%

Outset Medical, Inc. (NASDAQ:OM) saw a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 1,915,455 shares, a decline of 13.6% from the February 12th total of 2,217,364 shares. Based on an average trading volume of 247,824 shares, the short-interest ratio is presently 7.7 days. Approximately 10.7% of the shares of the company are sold short. Approximately 10.7% of the shares of the company are sold short. Based on an average trading volume of 247,824 shares, the short-interest ratio is presently 7.7 days.

Outset Medical Trading Up 8.4%

Shares of OM traded up $0.28 during mid-day trading on Tuesday, reaching $3.63. 113,227 shares of the company’s stock traded hands, compared to its average volume of 866,592. The company has a debt-to-equity ratio of 0.76, a current ratio of 6.67 and a quick ratio of 5.40. The stock’s 50-day moving average is $4.25 and its two-hundred day moving average is $7.78. Outset Medical has a 12 month low of $3.00 and a 12 month high of $21.98. The stock has a market cap of $66.47 million, a P/E ratio of -0.53 and a beta of 2.13.

Analyst Upgrades and Downgrades

OM has been the topic of a number of research analyst reports. BTIG Research decreased their target price on Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $7.00 target price on shares of Outset Medical in a research report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. Stifel Nicolaus dropped their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 7th. Finally, Wall Street Zen downgraded shares of Outset Medical from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Insider Activity at Outset Medical

In related news, CEO Leslie Trigg sold 11,794 shares of Outset Medical stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $60,385.28. Following the transaction, the chief executive officer directly owned 107,823 shares in the company, valued at approximately $552,053.76. The trade was a 9.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel John L. Brottem sold 9,314 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $47,687.68. Following the transaction, the general counsel owned 36,957 shares of the company’s stock, valued at approximately $189,219.84. This trade represents a 20.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 40,910 shares of company stock worth $193,040. 2.40% of the stock is owned by insiders.

Institutional Trading of Outset Medical

Institutional investors and hedge funds have recently made changes to their positions in the business. BML Capital Management LLC bought a new position in Outset Medical during the 4th quarter worth about $2,015,000. Pura Vida Investments LLC raised its holdings in shares of Outset Medical by 8,482.4% in the 2nd quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock valued at $8,243,000 after purchasing an additional 424,120 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Outset Medical in the 3rd quarter worth approximately $5,324,000. Geode Capital Management LLC lifted its position in shares of Outset Medical by 955.9% in the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock worth $7,984,000 after purchasing an additional 376,196 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Outset Medical by 165.8% during the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after purchasing an additional 262,874 shares in the last quarter.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.